Evaluation of the Clinical and Economic Impact of painPRIMER in the Treatment of Low Back Pain in a Primary Care Setting

Stopped early

Conditions studied: Low Back Pain

In brief

To evaluate the impact of painPRIMER in a prospective six-month clinical investigation looking at clinical outcomes, health care professional and patient satisfaction, healthcare resource use, productivity and direct and indirect costs. The hypothesis is that early identification of the presence of neuropathic pain and back pain related comorbidities, to direct appropriate pharmacologic and non-pharmacologic treatment, painPRIMER would improve patient outcomes and reduce patient cycling, inappropriate use of imaging and surgery, thereby reducing costs and productivity loss associated with these inefficiencies.

Key facts

Study ID

NCT01838057

Run by

Pfizer

People needed

103

Starts

2013-06-01

Expected to finish

2014-07-01

Last updated by the study team

2015-04-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Those aged 18 years of age
• Presenting to a HCP with low back pain
• Able to speak, write, and understand both verbal and written English

You may not qualify if…

• Conditions that may impede the patient's ability to participate in painPRIMER and complete the questionnaires, as per the HCP's discretion
• Patients presenting who have undergone surgery for back pain in the previous 12 months
• Patients with Medicare as their primary insurance

Where it is running

• Pfizer Investigational Site — Fayetteville, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.